1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Relapsing Refractory Multiple Myeloma- Epidemiology Forecast to 2028

Relapsing Refractory Multiple Myeloma- Epidemiology Forecast to 2028

  • September 2019
  • 80 pages
  • ID: 5816578
  • Format: PDF
  • By Delve Insight

Summary

Table of Contents

‘Relapsing Refractory Multiple Myeloma- Epidemiology Forecast to 2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Relapsing Refractory Multiple Myeloma in Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia).

Geography Covered

• Asia (China and Taiwan)
• Middle East (Saudi Arabia and UAE)
• Eastern Europe (Russia and Turkey)
• LATAM (Mexico, Brazil, Argentina and Columbia)

Study Period: 2017–2028
Relapsing Refractory Multiple Myeloma - Disease Understanding
Multiple Myeloma (MM) is the second most incident hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from an accumulation of terminally differentiated monoclonal plasma cells (PC) in the bone marrow. The mechanism of action of MM characterized by the unusual increase of monoclonal paraprotein leading to evidence of specific end-organ damage. The majority of patients with multiple myeloma (MM) will have an initial response to treatment with modern combination regimens. However, conventional therapy is not curative and most of these patients will ultimately progress. In addition, some patients will not respond to initial treatment (i.e., refractory disease). Relapsed or refractory MM is usually identified through routine monitoring with laboratory studies. The signs and symptoms of Multiple Myeloma include hypercalcemia, renal insufficiency, anemia, lytic bony lesions along with a monoclonal protein in the serum, increase in the number of clonal plasma cells in the bone marrow, etc.
The Relapsing Refractory Multiple Myeloma market report gives the thorough understanding of the Relapsing Refractory Multiple Myeloma by including details such as disease introduction, symptoms of multiple myeloma, molecular classification of Multiple Myeloma, stages of multiple myeloma, pathogenesis, pathophysiology, biomarkers for multiple myeloma, diagnosis and patient-related risk factors.

Relapsing Refractory Multiple Myeloma Epidemiology

The Relapsing Refractory Multiple Myeloma epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 major emerging markets (EM). The epidemiology data for Relapsing Refractory Multiple Myeloma are studied through all possible division to give a better understanding about the disease scenario in 10 EM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Relapsing Refractory Multiple Myeloma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Relapsing Refractory Multiple Myeloma in 10 EM covering Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia) from 2017–2028 for the following aspects:
• Diagnosed Incident cases of Multiple Myeloma (MM)
• Gender-specific Diagnosed Incidence of Multiple Myeloma (MM)
• Diagnosed Incident Multiple Myeloma (MM) Population on Second Line of Treatment
• Diagnosed Incident Multiple Myeloma (MM) Population on Third Line (and above) of Treatment
• Total Diagnosed Incident RRMM cases
There are several potential research papers and studies evaluated in order to analyze the overall epidemiology trend in the emerging markets. Few are listed below:
Lu et al. conducted a study “Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis” with the aim to understand the clinical features and treatment outcome of Chinese patients with multiple myeloma (MM). As per the study, if the Japanese incidence of MM is applied to China, there would be an estimated 27,800 new cases (1.39 billion × 2 per 100,000) each year and a total of 200,000 cases in China. With the acceleration of the aging process in China, it is predicted that MM, with rapid growth in incidence, will become one of the more significant diseases that affect people’s health in the country. It has also been reported that immigrants from Asia living in the USA have an increased incidence of MM compared with those living in Asia.
Hungria et al. suggest that Multiple Myeloma (MM) is a disorder characterized by abnormal clonal proliferation of plasmocytes in the bone marrow resulting in the production of monoclonal immunoglobulins associated with organic disorders. MM accounts for 1% of all neoplastic diseases and 13% of hematologic neoplasms as stated in “Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira – 2012.” In Brazil, there is no exact knowledge of the incidence of this disease.

Report Scope

• The report covers detailed overview of Relapsing Refractory Multiple Myeloma explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns.
• The report provides the insight about the historical and forecasted patient pool for 10 emerging markets covering Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia).
• The Report assesses the disease risk and burden and highlights the unmet needs of Relapsing Refractory Multiple Myeloma.
• The Report helps to recognize the growth opportunities in 10 EM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology by type specific cases and severity specific cases of Relapsing Refractory Multiple Myeloma in 10 EM.

Key strengths

• 10 Year Forecast of Relapsing Refractory Multiple Myeloma epidemiology
• 10 EM Coverage
• Total Incident Cases of Relapsing Refractory Multiple Myeloma
• Incident Cases according to segmentation

Key assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($3750)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Macrophage Stimulating Protein Receptor - Pipeline Review, H2 2019

Macrophage Stimulating Protein Receptor - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Macrophage Stimulating Protein Receptor - Pipeline Review, H2 2019SummaryMacrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) pipeline ...

Lymphoma Treatment Drugs Markets in China

Lymphoma Treatment Drugs Markets in China

  • $ 4000
  • October 2019

China’s demand for Lymphoma Treatment Drugs has grown at a fast pace in the past decade.In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed ...

Encephalomyelitis - Pipeline Review, H2 2019

Encephalomyelitis - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Encephalomyelitis - Pipeline Review, H2 2019SummaryPharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H2 2019, provides an overview of the Encephalomyelitis (Central ...


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on